Home » Department of Pharmaceuticals Rejects Drug Price Review Pleas of Dr. Reddy’s, Abbott

Department of Pharmaceuticals Rejects Drug Price Review Pleas of Dr. Reddy’s, Abbott

October 30, 2013

India’s Department of Pharmaceuticals has rejected a petition by Dr. Reddy’s and Abbott against fixing ceiling prices of drugs.
The Economic Times

21Apr
CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health
26Apr
MAGI's Clinical Research vConference — Spring 2021
06May
The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next
12May
Extractables and Leachables: 101
25May
How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Department of Pharmaceuticals Rejects Drug Price Review Pleas of Dr. Reddy’s, Abbott

Upcoming Events

CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

MAGI's Clinical Research vConference — Spring 2021

The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Extractables and Leachables: 101

How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

EMA Reviews GSK’s and Vir’s VIR-7831 for COVID-19

Hensler Surgical Technologies Earns CE Mark for Bone-Fusion Device

Eli Lilly Asks FDA to Nix EUA for Bamlanivimab Alone

Alimetry Earns CE Mark for Wearable Gastric Disease Diagnostic

The Revised ICH E8: A Guide to New Clinical Trial Requirements